1BSL01AE — Biotika as Income Statement
0.000.00%
Last trade - 00:00
- €16.80m
- €14.20m
- €11.03m
- 65
- 53
- 22
- 40
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 26 | 19.9 | 17.6 | 8.91 | 11 |
Cost of Revenue | |||||
Gross Profit | 12.8 | 11.1 | 9.91 | 7.03 | 5.74 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 24.4 | 18 | 15.5 | 8.44 | 12.1 |
Operating Profit | 1.63 | 1.94 | 2.16 | 0.472 | -1.08 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.47 | 2.5 | 2.73 | 0.515 | -0.843 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.13 | 2.02 | 2.28 | 0.406 | -0.82 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.13 | 2.02 | 2.28 | 0.406 | -0.82 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.13 | 2.02 | 2.28 | 0.406 | -0.82 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.72 | 2.81 | 3.23 | 0.576 | -1.19 |
Dividends per Share |